Stockreport

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease [Yahoo! Finance]

VACCINEX INC  (VCNX) 
PDF to treating Alzheimer's disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue shar [Read more]